.

Iran breaks US monopoly on stroke drug production

Alteplase, an effective drug for the treatment of acute ischemic stroke, had been a US monopoly, but Iranian researchers have recently succeeded in producing it.

Alteplase, which is approved by the US Food and Drug Administration, has been marketed under the brand name Altelyse by the knowledge-based company Arena Life Science.
According to the chairman of the board of directors of Arena Life Science, if this drug is injected into the patient within the first three hours after a stroke, it can significantly prevent the occurrence of complications and disabilities caused by the stroke. The drug is also very effective for the treatment of heart attacks and pulmonary embolism.
The quality of the company's products has satisfied patients and doctors, and this is our most important achievement in the pharmaceutical field of the country.
Importing this drug to Iran cost $10 million annually. With the introduction of this product into the treatment cycle and the cessation of imports, Iran will save foreign exchange, create jobs, and generate significant foreign exchange through exports to neighboring countries and European markets.
In addition, producing the drug in Iran will make it available to the markets of Iran and other countries at a lower price.

Similar English source:
https://www.presstv.ir/Detail/2023/09/27/711611/Iran-Alteplase-Altelyse-stroke-medicine--

the Iranian company’s website:
https://arenalifescience.com